| Clinical data | |
|---|---|
| Trade names | Monoferric, Monofer |
| Other names | FDI |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C18H34FeO16+3 |
| Molar mass | 562.299 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ferric derisomaltose, sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). [4] It was approved for use in the United States in January 2020. [4] [5] [6] It is given intravenously. [4]